. Transgenic mice that overexpress clinical mutants of the human amyloid precursor protein (APP) have been generated that recapitulate many aspects of AD. We now analyzed the cholinergic system in aged APP/London transgenic mice. The major finding was the reorganization of acetylcholinesterase-positive fibers within the hippocampus and the reduced size of cholinergic cells in the medial septum. The reduction of acetylcholinesterase-positive fibers in the subiculum together with increased fiber density in the CA1 and in the dentate gyrus suggests a synaptic sprouting compensatory mechanism within the hippocampus. In the cortex, amyloid plaques were associated with intense acetylcholinesterase activity and surrounded by dystrophic acetylcholinesterase-positive fibers. Nevertheless, the overall pattern of cholinergic innervation was unchanged. These results demonstrate that overexpression of APP/London caused, besides amyloid plaques in aged mouse brain, also cholinergic deafferentation and cholinergic cell shrinkage.
INTRODUCTION
Alzheimer's disease (AD) is the most common type of dementia (75%), manifesting as a severe deterioration of mental functions (Cummings & Kaufer, 1996) . Familial AD patients are due to mutations in the amyloid precursor protein (APP) and in the presenilin genes. Most AD patients are sporadic cases (PericakVance & Haines, 1995) .
Postmortem AD brain is characterized by the presence of amyloid plaques, neurofibrillary tangles, synaptic loss and cell loss, and neurotransmitter derangement. The amyloid plaques are extracellular deposits of A␤ peptide, a proteolytic fragment of APP (Haass & Selkoe, 1993) . Neurofibrillary tangles are intracellular aggregates formed by a hyperphosphorylated form of the microtubule-associated protein tau (Goedert, 1993) . A consistent neurotransmitter derangement in AD is the cholinergic deficit (Geula & Mesulam, 1994; Procter et al., 1996) . The cholinergic problem continues to attract interest because its magnitude correlates with the severity of dementia (Perry et al., 1978; Bierer et al., 1995) . Drugs that target the cholinergic system are at this moment the main type of drugs available to treat the symptoms of AD (Parnetti et al., 1997; Francis et al., 1999) .
Several transgenic mice models overexpressing APP and its clinical mutants have been generated which recapitulate aspects of AD. Amyloid plaques and neuritic changes have been obtained in addition to astrogliosis, microglial activation and increased tau phos-
